Cytokine release syndrome after CAR infusion in pediatric patients with refractory/relapsed B-ALL: is there a role for diclofenac?

1. Gan, TJ. Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin 2010; 26: 1715–1731.
Google Scholar | Crossref | Medline2. Altman, R, Bosch, B, Brune, K, et al. Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology. Drugs 2015; 75: 859–877.
Google Scholar | Crossref | Medline3. Pesenti, A, Riboni, A, Basilico, E, et al. Antipyretic therapy in ICU patients: evaluation of low dose diclofenac sodium. Intens Care Med 1986; 12: 370–373.
Google Scholar | Crossref | Medline4. Cormio, M, Citerio, G, Spear, S, et al. Control of fever by continuous, low-dose diclofenac sodium infusion in acute cerebral damage patients. Intens Care Med 2000; 26: 552–557.
Google Scholar | Crossref | Medline5. Paramba, FC, Naushad, VA, Purayil, N, et al. Randomized controlled study of the antipyretic efficacy of oral paracetamol, intravenous paracetamol, and intramuscular diclofenac in patients presenting with fever to the emergency department. Ther Clin Risk Manag 2013; 9: 371–376.
Google Scholar | Crossref | Medline6. Gödel, P, Shimabukuro-Vornhagen, A, Von Bergwelt-Baildon, M. Understanding cytokine release syndrome. Intens Care Med 2018; 44: 371–373.
Google Scholar | Crossref | Medline7. Tanaka, T, Narazaki, M, Kishimoto, T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 2016; 8: 959–970.
Google Scholar | Crossref | Medline8. Teachey, DT, Lacey, SF, Shaw, PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 2016; 6: 664–679.
Google Scholar | Crossref | Medline9. Lee, DW, Santomasso, BD, Locke, FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019; 25: 625–638.
Google Scholar | Crossref | Medline10. Teachey, DT, Rheingold, SR, Maude, SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013; 121: 5154–5157.
Google Scholar | Crossref | Medline11. Lee, DW, Gardner, R, Porter, DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124: 188–195.
Google Scholar | Crossref | Medline12. Kochenderfer, JN, Dudley, ME, Feldman, SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119: 2709–2720.
Google Scholar | Crossref | Medline13. National Cancer Institute . Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. National Cancer Institute.
Google Scholar14. Porter, DL, Hwang, WT, Frey, NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015; 7: 303ra139.
Google Scholar | Crossref | Medline15. Mayordomo-Colunga, J, Pons, M, López, Y, et al. Predicting non-invasive ventilation failure in children from the SpO2/FiO2 (SF) ratio. Intens Care Med 2013; 39: 1095–1103.
Google Scholar | Crossref | Medline16. Rice, TW, Wheeler, AP, Bernard, GR, et al. Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. Chest 2007; 132: 410–417.
Google Scholar | Crossref | Medline17. Davila, ML, Riviere, I, Wang, X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6: 224ra25.
Google Scholar | Crossref | Medline18. Litalien, C, Jacqz-Aigrain, E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol. Paediatr Drugs 2001; 3: 817–858.
Google Scholar | Crossref | Medline19. Vuori, A, Salo, M, Viljanto, J, et al. Effects of post-operative pain treatment using non-steroidal anti-inflammatory analgesics, opioids or epidural blockade on systemic and local immune responses in children. Acta Anaesthesiol Scand 2004; 48: 738–749.
Google Scholar | Crossref | Medline20. Brudno, JN, Kochenderfer, JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016; 127: 3321–3330.
Google Scholar | Crossref | Medline21. Frey, NV, Porter, DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2016; 2016: 567–572.
Google Scholar | Crossref | Medline22. Hay, KA . Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR) T cell therapy. Br J Haematol 2018; 183: 364–374.
Google Scholar | Crossref | Medline23. Maude, SL, Laetsch, TW, Buechner, J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018; 378: 439–448.
Google Scholar | Crossref | Medline24. Stephan, A, Maude, SL, Rives, S, et al. Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia. ASH; 2018.
Google Scholar25. Le, RQ, Li, L, Yuan, W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell induced severe or life threatening cytokine release syndrome. Oncologist 2018; 23: 943–947.
Google Scholar | Crossref | Medline26. Anderson, SK and Al Shaikh BA. Diclofenac in combination with opiate infusion after joint replacement surgery. Anaesth Intens Care 1991 Nov; 19: 535–538.
Google Scholar | SAGE Journals

留言 (0)

沒有登入
gif